TEIJIN PHARMA LIMITED | News Release /pressrelease/rss.xml Teijin Pharma News Release ja TEIJIN PHARMA LIMITED Feb. 17, 2026 Teijin Pharma and Aska Pharmaceutical Enter Joint Research Agreement to Accelerate Discovery of Novel Small-Molecule Drug Candidates for Gynecological Diseases https://www.teijin-pharma.com/pressrelease/2026/20260217.html TEIJIN PHARMA LIMITED Feb. 17, 2026 Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Weekly Pediatric Growth Hormone Deficiency Treatment https://www.teijin-pharma.com/pressrelease/2026/20260212.html TEIJIN PHARMA LIMITED Feb. 12, 2026 Teijin Pharma to Receive $5 Million Milestone Payment from Bioprojet for Initiating Phase 1 Clinical Trial of Narcolepsy Drug Candidate https://www.teijin-pharma.com/pressrelease/2025/20251127.html TEIJIN PHARMA LIMITED Nov. 27, 2025 Teijin Pharma Launches YORVIPATH®, a First of its Kind Treatment in Japan for the Rare Disease Hypoparathyroidism https://www.teijin-pharma.com/pressrelease/2025/20251106.html TEIJIN PHARMA LIMITED Nov. 06, 2025 Teijin Pharma Signs Licensing Agreement Giving UK Biotech Firm Exclusive Global Development and Commercialization Rights to Rheumatoid Arthritis Drug Candidate https://www.teijin-pharma.com/pressrelease/2025/20251023.html TEIJIN PHARMA LIMITED Oct. 23, 2025 Teijin Pharma Receives Manufacturing and Marketing Approval in Japan for YORVIPATH® as the Treatment for Hypoparathyroidism https://www.teijin-pharma.com/pressrelease/2025/20250825.html TEIJIN PHARMA LIMITED Aug. 25, 2025 Teijin Pharma Receives Approval for Additional Indication for XEOMIN® in Japan https://www.teijin-pharma.com/pressrelease/2025/20250624.html TEIJIN PHARMA LIMITED Jun. 24, 2025 Navepegritide Designated as an Orphan Drug by Japan’s Ministry of Health, Labor and Welfare https://www.teijin-pharma.com/pressrelease/2025/20250603.html TEIJIN PHARMA LIMITED Jun. 03, 2025 Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Hypoparathyroidism Treatment https://www.teijin-pharma.com/pressrelease/2024/20241213.html TEIJIN PHARMA LIMITED Dec. 13, 2024 Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy https://www.teijin-pharma.com/pressrelease/2024/20240410.html TEIJIN PHARMA LIMITED Apr. 10, 2024